|
Mortality in adult patients with solid or hematological cancers and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: A systematic review and meta-analysis. |
|
|
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche; Takeda |
Other Relationship - Amgen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Covance |
|
|
Honoraria - Roche/Genentech; Seagen; Zodiac Pharma |
Consulting or Advisory Role - Libbs; Novartis; Pierre Fabre; Roche/Genentech |
Research Funding - AstraZeneca (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst); Servier/Pfizer (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche/Genentech |
|
|
Honoraria - Lilly (Inst); Lilly (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer; Pfizer (Inst); Pfizer (Inst); Roche (Inst) |
Consulting or Advisory Role - AstraZeneca (Inst); Lilly (Inst); Lilly (Inst); Novartis; Novartis; Novartis; Novartis (Inst); Novartis (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Teva (Inst); Vifor Pharma (Inst) |
Research Funding - Sanofi (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; PharmaMar; Roche; Roche; Roche; Roche |
|
|
|
Consulting or Advisory Role - Roche; Shire |
Research Funding - Boehringer Ingelheim (Inst) |
Travel, Accommodations, Expenses - Array BioPharma; Celgene; Halozyme; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Lilly; MSD Oncology; Novartis; Roche |
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen |
Travel, Accommodations, Expenses - Celgene; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Roche |
Speakers' Bureau - Lilly; Novartis; Pfizer; Roche; Sandoz; Takeda; Theramex |